

Cases from the Community: Investigators Discuss Available Research Guiding the Care of Patients with Ovarian and Endometrial Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Raludotatug deruxtecan (R-DXd) is an antibody-drug conjugate directed against...
  - a. FR $\alpha$
  - b. CDH6
  - c. HER2
  - d. XPO1
2. The Phase III SIENDO trial revealed a statistically significant reduction in the risk of progression or death for patients with endometrial cancer (EC) receiving selinexor in which of the following settings?
  - a. As monotherapy after disease progression on first-line chemotherapy
  - b. As maintenance after induction chemotherapy
  - c. In combination with pembrolizumab for recurrent disease
  - d. As monotherapy after 3 or more prior lines of treatment
3. What was the approximate objective response rate with trastuzumab deruxtecan for patients with HER2 IHC 3+ advanced EC in the Phase II DESTINY-PanTumor02 study?
  - a. 25%
  - b. 40%
  - c. 65%
  - d. 85%
4. Which of the following adverse events is most commonly associated with R-DXd?
  - a. Headache
  - b. Pneumonitis
  - c. Rash
  - d. Nausea
5. Which of the following descriptions best reflects results of the Phase III ROSELLA trial of relacorilant with *nab* paclitaxel for patients with platinum-resistant ovarian cancer?
  - a. No significant improvement in progression-free survival (PFS) or overall survival (OS)
  - b. Significant improvement in PFS only
  - c. Significant improvements in both PFS and OS